Cancer care for Ukrainian refugees: Strategic impact assessments in the early days of the conflict

Autor: M. Van Hemelrijck, L. Fox, K. Beyer, E. Fedaraviciute, G. George, H. Hadi, A. Haire, J. Handford, A. Mera, M.J. Monroy-Iglesias, C.L. Moss, N. Perdek, B. Russell, A. Santaolalla, M. Sztankay, H. Wylie, J. Jassem, M. Zubaryev, B.O. Anderson, R. Ortiz, A. Ilbawi, R. Camacho, C. Ferreira-Borges, F. Roitberg, A.E. Dvaladze, M. Lasierra Losada, F. Alves da Costa, A. Aggarwal, M. Lawler, S. Kopetskiy, R. Sullivan

Publikováno v: Van Hemelrijck, M, Fox, L, Beyer, K, Fedaraviciute, E, George, G, Hadi, H, Haire, A, Handford, J, Mera, A, Monroy-Iglesias, M J, Moss, C L, Perdek, N, Russell, B, Santaolalla, A, Sztankay, M, Wylie, H, Jassem, J, Zubaryev, M, Anderson, B O, Ortiz, R, Ilbawi, A, Camacho, R, Ferreira-Borges, C, Roitberg, F, Dvaladze, A E, Lasierra Losada, M, Alves da Costa, F, Aggarwal, A, Lawler, M, Kopetskiy, S & Sullivan, R 2022, ' Cancer care for Ukrainian refugees: Strategic impact assessments in the early days of the conflict ', Journal of Cancer Policy, vol. 34, 100370 . https://doi.org/10.1016/j.jcpo.2022.100370

The invasion of Ukraine by Russia in February 2022 has resulted in destruction of healthcare infrastructure and triggered the largest wave of internally displaced populations and refugees since World War Two. Conflicts in transitioned countries such

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e45923581352cd5af5603ce902a6d893
https://pubmed.ncbi.nlm.nih.gov/36375808

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up

Autor: S. Loibl, J. Jassem, A. Sonnenblick, D. Parlier, E. Winer, J. Bergh, R.D. Gelber, E. Restuccia, Y-H. Im, C. Huang, F. Dalenc, I. Calvo, M. Procter, C. Caballero, E. Clark, H.L. Gomez Moreno, J. Bliss, G. Viale, J. Bines, M. Piccart

Publikováno v: Annals of Oncology. 33:986-987

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::73a9df3d7de472b4de4db0b77086f795
https://doi.org/10.1016/j.annonc.2022.06.009

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

166MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from BEGONIA, a phase Ib/II study

Autor: P. Schmid, K.H. Jung, P.J. Wysocki, J. Jassem, C.X. Ma, R. Fernandes, R. Huisden, R. Stewart, P. Vukovic, A. Tablante Nunes, Z. Nowecki

Publikováno v: Annals of Oncology. 33:S199

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b97ea82151189f3756157a4f17eb9a79
https://doi.org/10.1016/j.annonc.2022.03.185